Effects of Dapagliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus. SUMS-ADDIT-2
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUMS-ADDIT-2
- 11 Jun 2019 Primary endpoint (Changes in body weight (BW) from baseline to week 24 (from 0 to 24 weeks) between the two groups: Dapagliflozin (Dapa) versus Standard treatment (Con)) has been met, according to results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 30 Apr 2019 Status changed from recruiting to active, no longer recruiting.